James Lah, MD, PhD
Associate Professor, Emory University Department of Neurology
This Phase II study is a randomized, double blind, placebo-controlled trial and employs gene therapy to deliver nerve growth factor (NGF) directly into the brain. The rationale behind this study is that NGF is known to promote survival of certain neurons, called cholinergic neurons, that degenerate in Alzheimer’s Disease (AD), and therefore may provide sustained functioning of these neurons. Direct delivery of Nerve Grownth Factor CERE-110 into the brain aims to selectively target the Nucleus Basalis of Meynert, where cholinergic neuronal degeneration occurs in AD. This clinical trial is enrolling people with mild to moderate Alzheimer’s disease. Potential enrollees must be stable on Alzheimer’s medications for three months and have a study partner who can attend all study visits.
For additional information on this study at the Emory Alzheimer’s Disease Research Center call Julie Kozarsky at 404-728-6589 or email email@example.com. The Alzheimer’s Disease Cooperative Study website has additional information at http://www.adcs.org/studies/ngf.aspx.
Allan Levey, MD, PhD
Director, Emory Alzheimer's Disease Research Center
Emory University Department of Neurology
In 2004 the Alzheimer’s Disease Neuroimaging Initiative (ADNI) began recruiting subjects into a five year study to identify biomarkers that were the earliest indicators of disease and that could most accurately track disease progression. Eight hundred volunteers were recruited 25% without memory complaints, 50% with Mild Cognitive Impairment and 25 % with a diagnosis of Alzheimer’s disease. The study was one of the largest of its kind supported by the National Institute of Aging in an innovative partnership with private industry. Study volunteers were followed every 6-12 months with detailed assessments of memory and other thinking abilities along with detailed brain imaging and collection of other biomarkers such as cerebrospinal fluid.
The project has proven so successful that in 2009 the National Institute of Aging funded an expansion of the study called ADNI Grand Opportunities (ADNI-GO) to include individuals with even earlier stages of Mild Cognitive Impairment. This past summer it was announced that the National Institute on Aging would be funding the second five year phase of ADNI now referred to as ADNI-2. This phase of the study will continue to follow the original ADNI subjects enrolled in 2004 but will also allow for recruitment of a new cohort of 550 new volunteers to continue the research efforts.
For more information about this research study, please call Janet Cellar at 404-728-6453 or email firstname.lastname@example.org.
James Herndon, PhD
Yerkes National Primate Research Center
The broad aim of the study is to examine how the aging process differentially affects females of three closely related primate species: humans, chimpanzees, and the rhesus monkey. Women who participate in the study undergo magnetic resonance (MRI) scanning, in addition to annual testing on a battery of tests designed to evaluate memory and other cognitive abilities. Healthy middle-aged and elderly women, as well as women that have been diagnosed with Mild Cognitive Impairment (MCI) or early Alzheimer’s disease will be enrolled in this research study.
For more information about this research study, please call CeeCee Manzanares at 404-727-9324 or email email@example.com.
Ken Hepburn, PhD
Emory University School of Nursing
Monica Parker, M.D.
Emory University School of Medicine
This is a research study of methods to improve the health and well being of African American Caregivers of persons with Alzheimer’s disease. Join us to benefit African American Caregivers of family members with Alzheimer’s Disease. Learn strategies for caregiving to help decrease stress. Increase your knowledge and awareness of self care in your caregiving. Become a part of improving the lives of caregivers in the African American community by enrolling in this research study
For additional information about this research study call the study coordinator at 404-727-8481.
James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center
Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center
The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking. By joining Honor you will learn about new research studies that are seeking volunteers. You will also receive our newsletter and invitations to educational events.
All Honor volunteers must have a “study partner” accompany them to their research visit. Your study partner will be asked questions about your memory and thinking. They will also be asked about your day to day functioning. A study partner is someone who has at least 10 hours of contact with you each week.
For more information about this research study, please call Marie Walters at 404-728-6950 or email firstname.lastname@example.org.
Monica Parker, MD
Assistant Professor, Emory University School of Medicine
The Registry for Remembrance (Remembrance study) is a special academic community partnership to educate and recruit African Americans for long term research participation at the Emory Alzheimer’s Disease Research Center (ADRC). As a Remembrance study volunteer, you will participate in a research study on memory. You will be informed of new research studies at the ADRC and have an opportunity to participate in research that focuses on understanding conditions that affect memory and thinking. You will also be on our mailing list to receive the ADRC’s bi-annual newsletter to be informed of educational events. For this research study, you will need to identify a person who can inform us about your memory and day to day functioning. This study informant should know you well enough to be able to answer questions about changes in your memory or ability to perform independent living functions.
For more information about this research study, please call LaShonda Strozier at 404-728-6395 or email email@example.com.